NCT06784921View on ClinicalTrials.gov

To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China.

Not yet recruitingOBSERVATIONAL

Enrollment

200

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2026

Conditions

Breast Cancer Metastatic

All Listed Sponsors

lead

Zhejiang Cancer Hospital

OTHER